/PRZWT/SHANGHAI, Dec. 9, 2024 - On the afternoon of Dec. 5, the 2024 Annual Investor Conference, hosted by Think Finance & Investor Network, was held in Shanghai. At the meeting, the list of "Golden Bridge Awards" was released. Yiling Pharmaceutical was awarded the title of "Golden Bridge Award · Outstanding New Quality Productivity Enterprise of the Year" for its outstanding performance in new quality productivity.
It is understood that the "Golden Bridge Award" has become one of the authoritative and influential awards in the investment market with its principles of trustworthiness, innovation and credibility and respect for the development laws of the capital industry. The award is based on the four dimensions of institutional performance, investment value, innovation ability and social responsibility. It aims to recognize the companies with the most investment value, innovation ability and development potential through scientific and rigorous research methods and justice and fairness.
After more than 30 years of innovation and development, Yiling Pharmaceutical has cultivated unique new productivity elements from theoretical innovation, technological innovation, chain innovation, market innovation, etc. Theoretical innovation is the "root" and "soul" of enterprise development, technological innovation is the "source" and "engine" of enterprise development, chain innovation is the "beam" and "pillar" of enterprise development, and market innovation is the "sail" and "paddle" of enterprise development. Promoting the high-quality development of Yiling Pharmaceutical has become a vivid practice for the Chinese medicine industry to lead the high-quality development of traditional Chinese medicine with new quality productivity.
